The 4,000-participant study will use a digital enrollment platform and will provide free genetic testing as well as support from doctors and genetics experts.
PGDx has the exclusive rights to develop both tissue- and blood-based diagnostics using MSK’s TMB-related intellectual property.
Researchers will use the company's Colvera assay to track biomarkers in rectal cancer patients before, during, and after treatment.
The collaborations will evaluate whether patient-specific ex vivo cancer immunotherapy assays can predict in vivo efficacy, and ACEA's cell analysis platform.
Scientists at Memorial Sloan Kettering Cancer Center, led by Gabriela Chiosis, revealed how the complexes are important for tumor survival in certain cases.